Hutchmed/$HCM
1D1W1MYTD1Y5YMAX
Capital at risk
About Hutchmed
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
- Ticker
- $HCM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,790
- Headquarters
- Hong Kong, Hong Kong
- Website
- www.hutch-med.com
Hutchmed Metrics
BasicAdvanced
$2.5B
677.07
$0.02
0.44
-
Price and volume
Market cap
$2.5B
Beta
0.44
52-week high
$17.29
52-week low
$9.77
Average daily volume
86K
Financial strength
Current ratio
5.644
Quick ratio
5.453
Long term debt to equity
0.057
Total debt to equity
0.074
Interest coverage (TTM)
-12.14%
Profitability
EBITDA (TTM)
-20.515
Gross margin (TTM)
13.31%
Net profit margin (TTM)
3.26%
Operating margin (TTM)
-6.33%
Effective tax rate (TTM)
8.25%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-1.24%
Return on equity (TTM)
1.46%
Valuation
Price to earnings (TTM)
677.068
Price to revenue (TTM)
21.475
Price to book
1.46
Price to tangible book (TTM)
1.46
Price to free cash flow (TTM)
1,185.294
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.012
Growth
Revenue change (TTM)
-8.81%
Earnings per share change (TTM)
-96.19%
3-year revenue growth (CAGR)
-10.16%
10-year revenue growth (CAGR)
10.61%
3-year earnings per share growth (CAGR)
-23.52%
10-year earnings per share growth (CAGR)
3.28%
Bulls say / Bears say
The China NMPA granted conditional approval for ORPATHYS® (savolitinib) to treat MET-amplified gastric cancer in patients who failed at least two prior therapies, addressing a niche 4–6% mutation-driven population. (Reuters)
Late-stage SANOVO Phase III data showed the ORPATHYS® plus TAGRISSO® combination significantly improved progression-free survival in first-line EGFR-mutated, MET-overexpressing NSCLC, validating HUTCHMED’s clinical collaboration and boosting its global franchise. (Reuters)
HUTCHMED locked in a $110 million upfront payment and up to $1.185 billion in milestone fees through an exclusive development and licensing agreement with GSK for its HMPL-A830 KRAS-EGFR-antibody conjugate, de-risking the ATTC platform and securing non-dilutive capital. (Reuters)
H1 2026 revenue was essentially flat at $278.3 million versus $277.7 million in H1 2025, underscoring stagnation in core product sales despite recent approvals and launches. (Reuters)
H1 2026 basic earnings per ADS collapsed to $0.09 from $2.65 in H1 2025, reflecting heavy reliance on one-off divestment gains for profitability and weaker operational earnings. (Reuters)
Goldman Sachs cut its 12-month price target on HCM to $14 from $16 in July 2026 and maintained a Neutral rating, signaling tempered analyst confidence in the stock’s near-term upside. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Upcoming events
No upcoming events
Hutchmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.